Masakazu Sugino

Masakazu Sugino

Auto-generated profile, based on publicly available information

Masakazu Sugino

National Center for Global Health and Medicine, Respiratory Medicine Tokyo Japan

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in Internal Medicine
Verified
Journal Article
Open access
PDF file
HMHideyuki Muraoka
Hideyuki Muraoka
NNNobuyuki Negoro
Nobuyuki Negoro
FTFumio Terasaki
Fumio Terasaki
TNTakahiro Nakakoji
Takahiro Nakakoji
SKShigeyuki Kojima
Shigeyuki Kojima
THToshiaki Hanafusa
Toshiaki Hanafusa
A 69-year-old man with a recurrent ventricular tachycardia (VT) was admitted. The patient was diagnosed as myotonic dystrophy type 1 (DM1) and DNA analysis revealed 1,800 CTG-repeat expansion in the myotonic dystrophy protein kinase (DMPK) gene. Ultrasonic cardiogram (UCG), left ventriculogram (LVG) and magnetic resonance imaging (MRI) did not show any abnormal sign including fatty infiltration. But, endomyocardial biopsy obtained from ventricular outflow tract revealed severe fatty infiltration and interstitial fibrosis. Radiofrequency catheter ablation at the biopsy site could eliminate VT, so it was strongly suggested that the re-entry circuit was formed by focal fatty-fibrosis. Careful observation should be continued for a long period.

7 May 2004 in Neuroscience Letters
Verified
Journal Article
Closed access
HNHideto Nakajima
Hideto Nakajima
MSMasakazu Sugino
Masakazu Sugino
FKFumiharu Kimura
Fumiharu Kimura
THToshiaki Hanafusa
Toshiaki Hanafusa
TIToshiyuki Ikemoto
Toshiyuki Ikemoto
ASAkira Shimizu
Akira Shimizu

13 October 2006 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
HNHideto Nakajima
Hideto Nakajima
MSM. Shimakage
M. Shimakage
YTY. Takeda
Y. Takeda
DFD. Furutama
D. Furutama
MSM. Sugino
M. Sugino
THT. Hanafusa
T. Hanafusa

1 January 1996 in Japanese Circulation Journal
Verified
Journal Article
Open access
YYYoshiharu Yamada
Yoshiharu Yamada
MSMasakazu Sugino
Masakazu Sugino
GKGenichi Kishima
Genichi Kishima
TTToshifumi Tanaka
Toshifumi Tanaka
AIAkitaka Iwagaki
Akitaka Iwagaki
ONOsamu Nakajima
Osamu Nakajima
An 87-year-old woman was admitted to our hospital on an emergency basis with atypical chest pain and dyspnea. She had a continuous precordial murmur. Electrocardiogram showed no evidence of myocardial ischemia, but chest X-ray showed marked enlargement of the cardiac silhouette and an abnormal calcified vascular structure. Computed tomography of the chest revealed large abnormal masses next to the heart. Two-dimensional echocardiography showed enlargement of the main trunk of the left coronary artery and 2 giant saccular aneurysms. Abnormal diastolic inflow to the main pulmonary trunk was also observed by color flow imaging. These findings were supported by data obtained using magnetic resonance imaging and transesophageal echocardiography. Based on the above findings, we diagnosed this case as a coronary artery fistula originating from the proximal left anterior descending artery associated with 2 giant saccular aneurysms draining into the pulmonary artery. To our knowledge, this is the oldest patient ever reported with such an anomaly. This case emphasizes that a good prognosis is possible even with a very pronounced visible structural abnormality.

1 June 2021 in Diabetes
Verified
Journal Article
Closed access
MYMami Yoshida
Mami Yoshida
AYAi Yoshida
Ai Yoshida
EOEriko Oh
Eriko Oh
NYNaomune Yamamoto
Naomune Yamamoto
ESEun Sasaki
Eun Sasaki
IKIkuo Koyama
Ikuo Koyama
Purpose: The purpose of this study is to assess the usefulness of liraglutide in elderly patients with type 2 diabetes to prevent progression of dementia. Methods: We retrospectively reviewed 31 outpatients with 65 years of age or older, who have been treated with liraglutide for 6 years (Group G; 12 males/19 females, 73.1 ± 8.6 years-old, HbA1c 7.5 ± 0.4%, 9 patients with cerebrovascular diseases, 8 patients with cardiovascular diseases, 16 patients with insulin therapy). Daily dose of liraglutide was 0.9 mg except 2 patients (0.6 mg). We examined Voxel-based Specific Regional Analysis System for Alzheimer’s Disease (VSRAD) on MRI, max-IMT measured by carotid artery ultrasonography, visceral fat area, concentrations of HbA1c and FPG, serum levels of CRP, HDL/LDL cholesterol, and TG, both before and after the treatment. Age, HbA1c, and VSRAD values-matched 16 patients who were treated with linagliptin were analyzed as a control (Group D). Results: After 6 years, VSRAD was significantly deteriorated in Group D (1.06±0.98→1.39±1.05 (p<0.01)) but not in Group G (1.28±0.80→1.39±1.1 (NS)). Max IMT and visceral fat are was significantly improved in Group G (2.41±1.50→2.09±0.84 (p<0.05), 141.1±57.2→127.2±52.9 (p<0.01)), but not in group D (2.04±1.01→1.99±0.68 (NS), 102.4±66.5→106.6±62.7cm2 (NS)). CRP was decreased in Group G (0.12±0.11→0.09±0.12mg/dl (p<0.01)). HbA1c (7.5±0.4 → 7.0±0.5 vs. 7.3±0.3 → 6.8±0.4%), FPG (137±19 → 121±11 vs. 129±12→110±15mg/dl), were significantly improved in both groups (p<0.01). No hypoglycemia requiring medical intervention was observed. Only TG in Group G (167±53→147±34mg/dl (p <0.01)) was improved in lipid parameters. During the 6 years, antidementia drugs were prescribed for 2 patients in both groups. A stroke event was found in a patient of Group D. Conclusion: Liraglutide possibly prevent progression of dementia. The reduction of visceral obesity may contribute to this beneficial effect through anti-arteriosclerosis. Disclosure M. Yoshida: None. A. Yoshida: None. E. Oh: None. N. Yamamoto: None. E. Sasaki: None. S. Yoshida: None. N. Ohsawa: None. M. Sugino: None. I. Koyama: None.

9 November 2024 in Respiratory Investigation
Verified
Journal Article
Closed access
HHHiroto Hatano
Hiroto Hatano
MSManabu Suzuki
Manabu Suzuki
MSMio Sugino
Mio Sugino
MNMikako Nakamura
Mikako Nakamura
YKYusaku Kusaba
Yusaku Kusaba
MHMasayuki Hojo
Masayuki Hojo